Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.

abstract：:Platinum-based compounds remain a well-established chemotherapy for cancer treatment despite their adverse effects which substantially restrict the therapeutic windows of the drugs. Both the cell type-specific toxicity and the clinical responsiveness of tumors have been associated with mechanisms that alter drug entry...

journal_title：Molecular oncology

authors： Melnikova M,Wauer US,Mendus D,Hilger RA,Oliver TG,Mercer K,Gohlke BO,Erdmann K,Niederacher D,Neubauer H,Buderath P,Wimberger P,Kuhlmann JD,Thomale J

更新日期：2020-04-01 00:00:00

abstract：:Modern technologies enable detection and characterization of circulating tumor cells (CTC) in peripheral blood samples. Thus, CTC have attracted interest as markers for therapeutic response in breast cancer. First studies have incorporated CTC analyses to guide therapeutic interventions and stratification of breast ca...

journal_title：Molecular oncology

authors： Gasch C,Oldopp T,Mauermann O,Gorges TM,Andreas A,Coith C,Müller V,Fehm T,Janni W,Pantel K,Riethdorf S

更新日期：2016-10-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of human cancer for which there are no effective therapies. Deep sequencing of PDAC tumors has revealed the presence of a high number of mutations (>50) that affect at least a dozen key signaling pathways. This scenario highlights the urgent need ...

journal_title：Molecular oncology

authors： Guerra C,Barbacid M

更新日期：2013-04-01 00:00:00

abstract：:Bone morphogenetic proteins (BMPs) are a group of growth factors with dual functions in cancer development and progression. Recently, certain tumor-promoting roles have been identified for selected antagonists/inhibitors (BMPIs) of this developmental pathway. A recent focus on the implication of BMP in colorectal canc...

journal_title：Molecular oncology

authors： Karagiannis GS,Treacy A,Messenger D,Grin A,Kirsch R,Riddell RH,Diamandis EP

更新日期：2014-10-01 00:00:00

abstract：:Breast cancer (BrCa) metabolism is geared toward biomass synthesis and maintenance of reductive capacity. Changes in glucose and glutamine metabolism in BrCa have been widely reported, yet the contribution of fatty acids (FAs) in BrCa biology remains to be determined. We recently reported that adipocyte coculture alte...

journal_title：Molecular oncology

authors： Balaban S,Lee LS,Varney B,Aishah A,Gao Q,Shearer RF,Saunders DN,Grewal T,Hoy AJ

更新日期：2018-09-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor most commonly associated with underlying chronic liver disease, especially hepatitis. It is a growing problem in the United States and worldwide. There are two potential ways to prevent HCC. Primary prevention which is based on vaccination or secondar...

journal_title：Molecular oncology

authors： Bupathi M,Kaseb A,Meric-Bernstam F,Naing A

更新日期：2015-10-01 00:00:00

abstract：BACKGROUND:Breast cancer is a heterogeneous disease with different molecular subtypes that have varying responses to therapy. An ongoing challenge in breast cancer research is to distinguish high-risk patients from good prognosis patients. This is particularly difficult in the low-grade, ER-positive luminal A tumors, w...

journal_title：Molecular oncology

authors： Montes de Oca R,Gurard-Levin ZA,Berger F,Rehman H,Martel E,Corpet A,de Koning L,Vassias I,Wilson LO,Meseure D,Reyal F,Savignoni A,Asselain B,Sastre-Garau X,Almouzni G

更新日期：2015-03-01 00:00:00

abstract：:A significant proportion of estrogen receptor-positive (ER+) breast cancer (BC) initially responds to endocrine therapy but eventually evolves into therapy-resistant BC. Transcription factor AP-2 gamma (TFAP2C) is a known regulator of ER activity, and high expression of TFAP2C is associated with a decreased response t...

journal_title：Molecular oncology

authors： Liu J,Liu Z,Li M,Tang W,Pratap UP,Luo Y,Altwegg KA,Li X,Zou Y,Zhu H,Sareddy GR,Viswanadhapalli S,Vadlamudi RK

更新日期：2020-12-02 00:00:00

abstract：:Targeted therapy for patients with HER2-positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failure, but little work...

journal_title：Molecular oncology

authors： Rye IH,Trinh A,Saetersdal AB,Nebdal D,Lingjaerde OC,Almendro V,Polyak K,Børresen-Dale AL,Helland Å,Markowetz F,Russnes HG

更新日期：2018-11-01 00:00:00

abstract：:The identification of novel antimetastatic therapeutic targets is necessary for improved treatment of patients with acquired BRAF inhibitor-resistant (BRAFi-R) melanoma, in whom metastasis is a major concern. Our present study focused on the identification of such targets to explore novel antimetastatic therapeutic op...

journal_title：Molecular oncology

authors： Mohapatra P,Prasad CP,Andersson T

更新日期：2019-02-01 00:00:00

abstract：:Angiogenin (ANG), a 14-kDa pro-angiogenic secreted protein, has been shown to play a role in cell migration and tumor invasion, which involve proteolytic cleavage of plasminogen to generate plasmin. However, the mechanism by which ANG regulates plasmin formation and cell migration was not known. Our studies here detec...

journal_title：Molecular oncology

authors： Dutta S,Bandyopadhyay C,Bottero V,Veettil MV,Wilson L,Pins MR,Johnson KE,Warshall C,Chandran B

更新日期：2014-05-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is marked by an abundant stromal deposition. This stroma is suspected to harbor both tumor-promoting and tumor-suppressing properties. This is underscored by the disappointing results of stroma targeting in clinical studies. Given the complexity of tumor-stroma interaction in PD...

journal_title：Molecular oncology

authors： Veenstra VL,Damhofer H,Waasdorp C,Steins A,Kocher HM,Medema JP,van Laarhoven HW,Bijlsma MF

更新日期：2017-08-01 00:00:00

abstract：:Recently, RNAs interacting with proteins have been implicated in playing an important role in the occurrence and progression of oesophageal squamous cell carcinoma (ESCC). In this study, we found that NELFA mRNA interacts with Rad17 through a novel noncoding mode in the nucleus and that the aberrant expression of USF2...

journal_title：Molecular oncology

authors： Xu J,Wang G,Gong W,Guo S,Li D,Zhan Q

更新日期：2020-03-01 00:00:00

abstract：:It is well known that different racial groups have significantly different incidence and mortality rates for certain cancers. It has been suggested that biological factors play a major role in these cancer racial disparities. Previous studies on the biological factors contributing to cancer racial disparity have gener...

journal_title：Molecular oncology

authors： Li Y,Pang X,Cui Z,Zhou Y,Mao F,Lin Y,Zhang X,Shen S,Zhu P,Zhao T,Sun Q,Zhang J

更新日期：2020-09-13 00:00:00

abstract：:We describe a cell damage-induced phenotype in mammary carcinoma cells involving acquisition of enhanced migratory and metastatic properties. Induction of this state by radiation required increased activity of the Ptgs2 gene product cyclooxygenase 2 (Cox2), secretion of its bioactive lipid product prostaglandin E2 (PG...

journal_title：Molecular oncology

authors： Gong J,Lang BJ,Weng D,Eguchi T,Murshid A,Borges TJ,Doshi S,Song B,Stevenson MA,Calderwood SK

更新日期：2018-08-01 00:00:00

abstract：:Cancer is a massive challenge with a significant impact on society, healthcare systems, the economy and an increasing number of patients and their families. To help meet this societal challenge, the European Commission has recently proposed a mission-oriented approach to cancer in Horizon Europe, and about 60 particip...

journal_title：Molecular oncology

authors： European Academy of Cancer Sciences.

更新日期：2019-03-01 00:00:00

abstract：:Thyroid transcription factor-1 (TTF-1, encoded by the NKX2-1 gene) is highly expressed in small-cell lung carcinoma (SCLC) and lung adenocarcinoma (LADC), but how its functional roles differ between SCLC and LADC remains to be elucidated. Here, we compared the genome-wide distributions of TTF-1 binding regions and the...

journal_title：Molecular oncology

authors： Hokari S,Tamura Y,Kaneda A,Katsura A,Morikawa M,Murai F,Ehata S,Tsutsumi S,Ishikawa Y,Aburatani H,Kikuchi T,Miyazono K,Koinuma D

更新日期：2020-02-01 00:00:00

abstract：:Endocytosis is an important regulator of cell-cell signaling and endocytic trafficking has been increasingly implicated in control of tumor suppression. Recent insights from Drosophila indicate that impairment of multiple trafficking steps which lead to receptor degradation can cause tumor formation in epithelial orga...

journal_title：Molecular oncology

authors： Vaccari T,Bilder D

更新日期：2009-08-01 00:00:00

abstract：:The PI3K/Akt signaling pathway, the most frequently altered signaling system in human cancer, is a crucial inducer of dysregulated proliferation and neoplastic processes; however, few therapeutic strategies using PI3K/Akt inhibitors singly have been shown to be effective. The purpose of this paper was to underline the...

journal_title：Molecular oncology

authors： Fabi F,Adam P,Parent S,Tardif L,Cadrin M,Asselin E

更新日期：2020-12-18 00:00:00

abstract：:Amplification of 3q26.2, found in many cancer lineages, is a frequent and early event in ovarian cancer. We previously defined the most frequent region of copy number increase at 3q26.2 to EVI1 (ecotropic viral integration site-1) and MDS1 (myelodysplastic syndrome 1) (aka MECOM), an observation recently confirmed by ...

journal_title：Molecular oncology

authors： Dutta P,Bui T,Bauckman KA,Keyomarsi K,Mills GB,Nanjundan M

更新日期：2013-06-01 00:00:00

abstract：:In breast cancer (BC), the presence of cancer stem cells (CSCs) has been related to relapse, metastasis, and radioresistance. Radiotherapy (RT) is an extended BC treatment, but is not always effective. CSCs have several mechanisms of radioresistance in place, and some miRNAs are involved in the cellular response to io...

journal_title：Molecular oncology

authors： Griñán-Lisón C,Olivares-Urbano MA,Jiménez G,López-Ruiz E,Del Val C,Morata-Tarifa C,Entrena JM,González-Ramírez AR,Boulaiz H,Zurita Herrera M,Núñez MI,Marchal JA

更新日期：2020-03-01 00:00:00

abstract：:Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated to the chromatin environment. In this context, our present work demonstrates that the pharmacological or genetic abrogation of HDAC6 in primary melanoma samples ...

journal_title：Molecular oncology

authors： M L,P PV,T K,M P,E S,J P,K V W,C L,F C,S D,M SKS,M M,A K,J PI,A S,E S,J W,E M S,A V

更新日期：2016-05-01 00:00:00

abstract：:Epigenetic silencing of miRNA is a primary mechanism of aberrant miRNA expression in cancer, and hypermethylation of miRNA promoters has been reported to contribute to prostate cancer initiation and progression. Recent data have shown that the miR-193b promoter is hypermethylated in prostate cancer compared with norma...

journal_title：Molecular oncology

authors： Mazzu YZ,Yoshikawa Y,Nandakumar S,Chakraborty G,Armenia J,Jehane LE,Lee GM,Kantoff PW

更新日期：2019-09-01 00:00:00

abstract：:Tumour suppressor p53, a master transcriptional regulator determines cell fate through preferential activation/repression of a myriad of genes during stress. Till date, activation and preferential binding of p53 on different promoters was reported to be influenced by the nature, strength and duration of stress which m...

journal_title：Molecular oncology

authors： Thakur B,Ray P

更新日期：2016-10-01 00:00:00

abstract：:Cancer is a multifactorial and heterogeneous disease. The corresponding complexity appears at multiple levels: from the molecular and the cellular constitution to the macroscopic phenotype, and at the diagnostic and therapeutic management stages. The overall complexity can be approximated to a certain extent, e.g. cha...

journal_title：Molecular oncology

authors： Dominietto M,Tsinoremas N,Capobianco E

更新日期：2015-01-01 00:00:00

abstract：:Pancreatic cancer is one of the most lethal human cancers, and radiotherapy is often implemented for locally advanced pancreatic ductal adenocarcinoma. Tumor cell repopulation is a major challenge in treating cancers after radiotherapy. In order to address the problem of tumor repopulation, our previous studies have d...

journal_title：Molecular oncology

authors： Cheng J,Tian L,Ma J,Gong Y,Zhang Z,Chen Z,Xu B,Xiong H,Li C,Huang Q

更新日期：2015-01-01 00:00:00

abstract：:In order to secure high-quality cancer care for increasing numbers of cancer patients in the upcoming decades, the complete continuum of cancer research and cancer care needs a thorough overhaul, with more emphasis on prevention and early detection, and a greater focus on the development of innovative treatments that ...

journal_title：Molecular oncology

authors： Berns A

更新日期：2019-03-01 00:00:00

abstract：:The ability to predict responsiveness to drugs in individual patients is limited. We hypothesized that integrating molecular information from databases would yield predictions that could be experimentally tested to develop transcriptomic signatures for specific drugs. We analyzed lung adenocarcinoma patient data from ...

journal_title：Molecular oncology

authors： Tavassoly I,Hu Y,Zhao S,Mariottini C,Boran A,Chen Y,Li L,Tolentino RE,Jayaraman G,Goldfarb J,Gallo J,Iyengar R

更新日期：2019-08-01 00:00:00

abstract：:Protein inhibitor of activated STAT3 (PIAS3) is an endogenous suppressor of signal transducer and activator of transcription 3 (STAT3) signaling. By directly interacting with phosphorylated STAT3, PIAS3 can block the downstream transcriptional activity of STAT3, which is hyper-activated in various cancers. We previous...

journal_title：Molecular oncology

authors： He T,McColl K,Sakre N,Chen Y,Wildey G,Dowlati A

更新日期：2018-12-01 00:00:00

abstract：:cMet is a well-characterized oncogene that is the target of many drugs including small molecule and biologic pathway inhibitors, and, more recently, antibody-drug conjugates (ADCs). However, the clinical benefit from cMet-targeted therapy has been limited. We developed a novel cMet-targeted 'third-generation' ADC, TR1...

journal_title：Molecular oncology

authors： Gymnopoulos M,Betancourt O,Blot V,Fujita R,Galvan D,Lieuw V,Nguyen S,Snedden J,Stewart C,Villicana J,Wojciak J,Wong E,Pardo R,Patel N,D'Hooge F,Vijayakrishnan B,Barry C,Hartley JA,Howard PW,Newman R,Coronella J

更新日期：2020-01-01 00:00:00